menu
    • menu
    [{"orgOrder":0,"company":"Orient Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Oxybutynin","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Neurology","graph2":"Phase II","graph3":"Orient Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Orient Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Orient Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Oxybutynin","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Urology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"ITALY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Oxybutynin","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Urology","graph2":"Phase IV","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Trigone Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Oxybutynin","moa":"||Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Urology","graph2":"Preclinical","graph3":"Trigone Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trigone Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Trigone Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxybutynin","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Urology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Gel","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Apnimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Oxybutynin","moa":"||Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apnimed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Undisclosed"},{"orgOrder":0,"company":"Universidad de Valparaiso","sponsor":"Uro Medical Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CHILE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Oxybutynin","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Urology","graph2":"Phase I","graph3":"Universidad de Valparaiso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Universidad de Valparaiso \/ Uro Medical Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Universidad de Valparaiso \/ Uro Medical Corporation"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Hospital Israelita Albert Einstein | University of Sao Paulo","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oxybutynin","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Dermatology","graph2":"Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Hospital Israelita Albert Einstein | University of Sao Paulo","highestDevelopmentStatusID":"10","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Hospital Israelita Albert Einstein | University of Sao Paulo"},{"orgOrder":0,"company":"Apnimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"||SLC6A2","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Apnimed \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for 4-[bis(1,1,2,2,2-pentadeuterioethyl)amino]but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate

    Menu

    4-[bis(1,1,2,2,2-pentadeuterioethyl)amino]but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AbbVie Inc

                            U.S.A
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxybutynin

                            Therapeutic Area : Urology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

                            Details : Oxybutynin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Urinary Bladder, Overactive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 01, 2010

                            Lead Product(s) : Oxybutynin

                            Therapeutic Area : Urology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Apnimed

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Apnimed

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxybutynin,Atomoxetin Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apnimed Eyes FDA Sleep Apnea Submission After Positive Results

                            Details : AD109 is a combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor (NRI) being investigated for OSA.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 19, 2025

                            Lead Product(s) : Oxybutynin,Atomoxetin Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Universidad de Valparaiso

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Universidad de Valparaiso

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxybutynin

                            Therapeutic Area : Urology

                            Study Phase : Phase I

                            Sponsor : Uro Medical Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effectiveness of Oral Boldo in Women With Overactive Bladder

                            Details : Oxybutynin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Urinary Bladder, Overactive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 08, 2023

                            Lead Product(s) : Oxybutynin

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I

                            Sponsor : Uro Medical Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Trigone Pharma

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Trigone Pharma

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxybutynin,Lidocaine

                            Therapeutic Area : Urology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trigone Pharma to Present Preclinical Data for TRG-100 in Interstitial Cystitis / Bladder Pain Syndrome at the...

                            Details : The in-vitro and animal data suggest that TRG-100 can safely be used for possible intravesical sustained release of Lidocaine and Oxybutynin in the treatment of BPS/IC.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 22, 2021

                            Lead Product(s) : Oxybutynin,Lidocaine

                            Therapeutic Area : Urology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Apnimed

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Apnimed

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Reboxetine Mesylate,Oxybutynin

                            Therapeutic Area : Sleep

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Data Presented at ATS Meeting Reinforces the Potential of an Oral Drug Combination Therapy for Obstructive Sle...

                            Details : Apnimed’s lead product candidate, AD109, targets the neurologic control and facilitates the activation of the upper airway dilator muscles to maintain an open airway during sleep.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 17, 2021

                            Lead Product(s) : Reboxetine Mesylate,Oxybutynin

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bayer AG

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxybutynin

                            Therapeutic Area : Urology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Th...

                            Details : Oxybutynin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Bladder, Overactive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 01, 2020

                            Lead Product(s) : Oxybutynin

                            Therapeutic Area : Urology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxybutynin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Hospital Israelita Albert Einstein | University of Sao Paulo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis

                            Details : Oxybutynin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperhidrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 31, 2014

                            Lead Product(s) : Oxybutynin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Hospital Israelita Albert Einstein | University of Sao Paulo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Janssen-Cilag

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Janssen-Cilag

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxybutynin

                            Therapeutic Area : Urology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity

                            Details : Oxybutynin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Urinary Bladder, Overactive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 21, 2013

                            Lead Product(s) : Oxybutynin

                            Therapeutic Area : Urology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Orient Pharma

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Orient Pharma

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxybutynin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

                            Details : Oxybutynin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sialorrhea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 10, 2011

                            Lead Product(s) : Oxybutynin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth